Guidance
← Отчётные звонки
01
02
03
04 05 06
Тон
AI
Капзатраты
A1 A2 A3
BMY
FY2026 Q1
Улучшается
Отчётный звонок Bristol-Myers Squibb Company
Вывод Buzzberg
Guidance tracking toward top end of 2026 ranges
Bristol-Myers Squibb's Q1 2026 earnings call highlighted solid performance across its growth portfolio, driven by launches like Qvantig and Breyanzi. Management reaffirmed full-year guidance, signaling confidence by indicating it expects to track towards the upper end of its financial ranges. The call focused heavily on upcoming pivotal readouts (e.g., milvexian, Cobenfi) and the company's strategy on a range of pipeline assets, including its oral cell mods, ADCs, and bispecifics. Total Q1 revenue grew 1% to $11.5B, with the growth portfolio up 9% to $6.2B, led by Breyanzi (+53%), Camzyos (nearly doubled), and Reblozyl (+15%).
Вывод Buzzberg Guidance tracking toward top end of 2026 ranges Bristol-Myers Squibb's Q1 2026 earnings call highlighted solid performance across its growth portfolio, driven by launches like Qvantig and Breyanzi. Management reaffirmed full-year guidance, signaling confidence by indicating it expects to track towards the upper end of its financial ranges. The call focused heavily on upcoming pivotal readouts (e.g., milvexian, Cobenfi) and the company's strategy on a range of pipeline assets, including its oral cell mods, ADCs, and bispecifics. Total Q1 revenue grew 1% to $11.5B, with the growth portfolio up 9% to $6.2B, led by Breyanzi (+53%), Camzyos (nearly doubled), and Reblozyl (+15%). Читать полный анализСвернуть анализ
Bristol-Myers Squibb's Q1 2026 earnings call highlighted solid performance across its growth portfolio, driven by launches like Qvantig and Breyanzi. Management reaffirmed full-year guidance, signaling confidence by indicating it expects to track towards the upper end of its financial ranges. The call focused heavily on upcoming pivotal readouts (e.g., milvexian, Cobenfi) and the company's strategy on a range of pipeline assets, including its oral cell mods, ADCs, and bispecifics. Total Q1 revenue grew 1% to $11.5B, with the growth portfolio up 9% to $6.2B, led by Breyanzi (+53%), Camzyos (nearly doubled), and Reblozyl (+15%).
- The company reaffirmed full-year 2026 guidance and stated it is tracking towards the upper end of its revenue and EPS ranges.
- Management expressed high confidence in the late-stage pipeline, particularly in upcoming readouts for milvexian (AFib/stroke) and Cobenfi (Alzheimer's psychosis), which are expected by year-end.
- The launch of Qvantig (subcutaneous Opdivo) is progressing well, with over 10% conversion from IV in the US and a target of 30-40% within two years.
GROWTH_PORTFOLIO Выручка$6.2BФакт
Выручка$11.489B-8% к/к
EPS$1.58+25% к/к
Валовая маржа70.22%Факт
6 подтверждённых тезисов
Что важно сейчас
Самые значимые изменения по итогам звонка.
Pipeline
Late-2026 pivotal readouts to define/de-risk growth
Pipeline
Milvexian hailed as true blockbuster opportunity
Показать ещё 3 тезиса
Cell Mods
Cell mod program advancing toward first market entry
Oncology Strategy
Pumitamig strategy: replace PD-1 and expand beyond
Capital Allocation
BD remains size-agnostic with financial flexibility
Отчётный период
Фактические результаты
| Показатель | Факт | Изменение |
|---|---|---|
| GROWTH_PORTFOLIO Выручка | $6.2B | Факт |
| Выручка | $11.489B | -8% к/к |
| EPS | $1.58 | +25% к/к |
| Валовая маржа | 70.22% | Факт |
| Операционная маржа | 29.29% | Факт |
| Свободный денежный поток | $0.757B | -53% к/к |
AI, капзатраты и спрос
Оценка менеджмента
Confident
Management repeatedly emphasized execution, momentum, and tracking toward the upper end of guidance, with conviction in late-stage pipeline catalysts.
Оценка AI от менеджмента
AI is discussed as an internal R&D productivity lever, not a product/monetization driver. Management cited broader use of AI tools, lab automation, and partnerships to streamline clinical operations, compress development timelines, and improve trial design.
Инвестиции и мощности
No explicit capex numbers were provided. Management qualitatively noted increased investment in core R&D infrastructure, including AI tools and laboratory automation, enabled partly by the remaining $2 billion Strategic Productivity Initiative savings.
все упомянутые компании ниже: 1
Компаниис момента звонка
Партнёры
Партнёры
Christian Massachese
BMY's partnership with BNTX on pimmitimig (a PD-1/VEGF bispecific) is progressing well, highlighting a strong collaborative relationship that could drive value for both companies.
Доказательства
“the partnership with BioNTech is moving very well because we are progressing the development of this drug with speed.”
Внешние сигналы
Альфа цепочки поставок · 3с момента звонка
Wholesaler inventory dynamics for Eliquis are expected to reverse in Q2, with a build in Q1 and anticipated drawdown, which could smooth out reported revenue trends.
Доказательства
“We also saw some wholesaler inventory build in the first quarter. We anticipate this build to reverse in the second quarter.”
A 10% conversion of Opdivo patients to Qvantig (subcutaneous) has already been achieved in the US, with a target of 30-40% conversion over the next two years.
Доказательства
“we've now delivered over 10% conversion from IV to Cuvantig in the U.S. in just over a year on the market and we're tracking well against our expectations and we remain confident in our expectation that physicians will convert approximatel…”
BMY is planning a new, more focused study in non-obstructive HCM, indicating a strategic pivot based on learnings from the Odyssey study, potentially enabling a more targeted and successful development path for Camzyos.
Доказательства
“So I want to announce that we are planning now to run a new, more focused study in non-obstructive HCM. And then, of course, the detail of it will be highlighted in clinicaltri.gov while we are progressing this work.”
Методология и полнота
Анализ основан только на заявлениях менеджмента. Показаны все подтверждённые упоминания компаний: 1. Фактические результаты и прогнозы разделены. Публичные доказательства ограничены восемью короткими атрибутированными цитатами. AI-анализ может быть неполным или ошибочным — проверяйте важные утверждения по первоисточнику.